Literature DB >> 23718901

The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia.

Shinichiro Sakata1, Michelle Cronk.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23718901     DOI: 10.1111/ajco.12077

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


× No keyword cloud information.
  2 in total

1.  Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer.

Authors:  Yat Hang To; Koen Degeling; Suzanne Kosmider; Rachel Wong; Margaret Lee; Catherine Dunn; Grace Gard; Azim Jalali; Vanessa Wong; Maarten IJzerman; Peter Gibbs; Jeanne Tie
Journal:  Pharmacoeconomics       Date:  2021-06-05       Impact factor: 4.981

2.  Inpatient care burden due to cancers in Anhui, China: a cross-sectional household survey.

Authors:  Ting Zhao; Jing Cheng; Jing Chai; Rui Feng; Han Liang; Xingrong Shen; Rui Sha; Debin Wang
Journal:  BMC Public Health       Date:  2016-04-11       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.